MDMA
Massachusetts Bill Would Cap MDMA Therapy Costs at $5,000
The article Massachusetts Bill Would Cap MDMA Therapy Costs at $5,000 was originally published on Microdose.
…Any person or entity registered to prescribe,…
The article Massachusetts Bill Would Cap MDMA Therapy Costs at $5,000 was originally published on Microdose.
…Any person or entity registered to prescribe, manufacture, distribute, dispense or provide services related to 3,4-methylenedioxymethamphetamine (MDMA) shall not charge more than $5,000 per MDMA treatment service unit.
This is the language used in bill HD2137, filed by Massachusetts State Representative. Nick Boldyga, a Republican, has proposed a bill that would not only re-schedule MDAM automatically upon FDA approval but cap the cost of treatment to $5,000.
The bill is at its earliest stage and has a ways to go, but it’s a sign that legislators (a Republicans at that) are taking the future of psychedelic medicine and access seriously.
As for cost concerns, according to several estimates and this piece in the Washington Post, the initial roll-out of MAPS’ MDMA therapy could reach $15,000.
If and when the FDA approves MDMA used for PTSD, it will not be widely available; it will be an option only for people with a formal clinical diagnosis of PTSD. It will also be incredibly expensive: Estimates range from $13,000 to $15,000 per treatment round, and it’s not clear what might be covered by health insurance.
With PTSD affecting people across all demographics, and with groups like veterans suffering disproportionately and not always having access to resources – questions of costs will be important. Will the VA (Veterans Association) cover MDMA therapy? Will regular insurance?
While legal price-capping might not be the solution, especially for a non-profit like MAPS, the conversation is an important one to have.
mdma psychedelic therapy ptsd fda
-
Law & Regulation1 week ago
Relmada Therapeutics trims losses, slashes research costs
-
Psychedelics1 week ago
Silo Pharma Exercises Option for Exclusive License Agreement for First-in-Class PTSD and Stress-Induced Anxiety Therapeutic
-
Psychedelics1 week ago
Numinus Wellness Submits Clinical Trial Application
-
Psychedelics1 week ago
Psyence Biomedical Ltd. Announces Results of Recent Study Highlighting Benefits of Nature Derived Psilocybin Vs. Synthetic Psilocybin
-
Psychedelics1 week ago
MindBio Therapeutics Corp. Begins Phase 2B Take-Home Microdosing Clinical Trial in Patients with Major Depressive Disorder
-
Psilocybin1 week ago
Indigenous Psilocybin Practices Around the World
-
Law & Regulation1 week ago
Gilgamesh secures $14M for ibogaine-like drug
-
Psychedelics1 week ago
Gilgamesh Receives Grant To Combat Opioid Dependency